Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

TSC-mutated sarcomas are rare molecular and histologic types of sarcoma. Due to the presence of their specific oncogenic driver mutation, these sarcomas are particularly sensitive to mTOR inhibitors. Recently, nab-sirolimus, an albumin-bound mTOR inhibitor, was approved by the Food and Drug Administ...

Full description

Bibliographic Details
Main Authors: Elise F. Nassif, Cissimol P. Joseph, Rossana Lazcano, Jocelyn T. Joseph, Prapassorn Thirasastr, Alexander J. Lazar, Neeta Somaiah
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
sarcoma
TSC
mTOR - mammalian target of rapamycin
gemcitabine
PEComa
nab-sirolimus
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1046442/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1046442/full

Similar Items